WallStreetZenWallStreetZen

NASDAQ: COCP
Cocrystal Pharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their COCP stock forecasts and price targets.

Forecast return on equity

Is COCP forecast to generate an efficient return?

Company
-1,185.68%
Industry
-14.66%
Market
156.52%
COCP's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is COCP forecast to generate an efficient return on assets?

Company
-266.26%
Industry
-1.84%
COCP is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

COCP earnings per share forecast

What is COCP's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.69
Avg 2 year Forecast
-$0.48
Avg 3 year Forecast
-$0.64

COCP revenue forecast

What is COCP's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$112.2k
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

COCP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
COCP$1.02N/AN/A
KYNB$4.85$36.80+658.76%Strong Buy
GUTS$1.55$72.00+4,545.16%Buy
QNTM$2.47$8.00+223.89%Strong Buy
ESLA$0.43N/AN/A
View Top Biotech Stocks

Cocrystal Pharma Stock Forecast FAQ

What is COCP's earnings growth forecast for 2026-2028?

(NASDAQ: COCP) Cocrystal Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.39%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 66.69%.

Cocrystal Pharma's earnings in 2026 is -$9,938,000.On average, 5 Wall Street analysts forecast COCP's earnings for 2026 to be -$13,295,461, with the lowest COCP earnings forecast at -$14,347,231, and the highest COCP earnings forecast at -$12,338,080. On average, 4 Wall Street analysts forecast COCP's earnings for 2027 to be -$9,333,020, with the lowest COCP earnings forecast at -$10,949,203, and the highest COCP earnings forecast at -$7,483,753.

In 2028, COCP is forecast to generate -$12,378,532 in earnings, with the lowest earnings forecast at -$11,893,100 and the highest earnings forecast at -$12,742,607.

If you're new to stock investing, here's how to buy Cocrystal Pharma stock.

What is COCP's revenue growth forecast for 2026-2028?

(NASDAQ: COCP) Cocrystal Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 42.83%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 15.58%.

Cocrystal Pharma's revenue in 2026 is $0.On average, 5 Wall Street analysts forecast COCP's revenue for 2026 to be $2,161,331, with the lowest COCP revenue forecast at $0, and the highest COCP revenue forecast at $6,674,699. On average, 4 Wall Street analysts forecast COCP's revenue for 2027 to be $0, with the lowest COCP revenue forecast at $0, and the highest COCP revenue forecast at $0.

In 2028, COCP is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is COCP's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: COCP) forecast ROA is -266.26%, which is lower than the forecast US Biotechnology industry average of -1.84%.

What is COCP's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: COCP) Cocrystal Pharma's current Earnings Per Share (EPS) is -$0.76. On average, analysts forecast that COCP's EPS will be -$0.69 for 2026, with the lowest EPS forecast at -$0.74, and the highest EPS forecast at -$0.64. On average, analysts forecast that COCP's EPS will be -$0.48 for 2027, with the lowest EPS forecast at -$0.57, and the highest EPS forecast at -$0.39. In 2028, COCP's EPS is forecast to hit -$0.64 (min: -$0.62, max: -$0.66).

What is COCP's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: COCP) forecast ROE is -1,185.68%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.